Neurocrine Biosciences - NBIX Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $128.52
Forecasted Upside: 16.68%
Number of Analysts: 21
Breakdown:
0 Sell Ratings
5 Hold Ratings
16 Buy Ratings
0 Strong Buy Ratings

^$110.15 As of 10/3/2023 11:39 AM ET

▼ -1.64 (-1.47%)

1 month | 3 months | 12 months

Get New Neurocrine Biosciences Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for NBIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBIX

^$128.52

▲ +16.68% Upside Potential

This price target is based on 21 analysts offering 12 month price targets for Neurocrine Biosciences in the last 3 months. The average price target is $128.52, with a high forecast of $154.00 and a low forecast of $95.00. The average price target represents a 16.68% upside from the last price of $110.15.

Current Consensus is Moderate Buy

The current consensus among 21 investment analysts is to moderate buy stock in Neurocrine Biosciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

4/10/2022

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

7/9/2022

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/7/2022

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

1/5/2023

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

4/5/2023

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

7/4/2023

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

9/2/2023

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/2/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/21/2023	Barclays	Boost Target		$125.00 ➝ $134.00	Low
9/13/2023	Mizuho	Reiterated Rating	Neutral ➝ Neutral	$113.00	Low
9/13/2023	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$132.00 ➝ $144.00	Low
9/13/2023	Robert W. Baird	Boost Target		$148.00 ➝ $152.00	Low
9/13/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$146.00	Low
9/13/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$136.00	Low
9/13/2023	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$133.00 ➝ $134.00	Low
9/13/2023	Wedbush	Boost Target	Outperform ➝ Outperform	$120.00 ➝ $137.00	Low
9/13/2023	BMO Capital Markets	Boost Target	Market Perform ➝ Market Perform	$100.00 ➝ $111.00	Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$136.00	Low
8/21/2023	Mizuho	Boost Target	Neutral	$112.00 ➝ $113.00	Low
8/21/2023	Jefferies Financial Group	Boost Target		$123.00	Low
8/21/2023	Oppenheimer	Boost Target	Outperform ➝ Outperform	$150.00 ➝ $154.00	Low
8/21/2023	HC Wainwright	Boost Target	Buy ➝ Buy	$140.00 ➝ $146.00	Low
8/2/2023	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$150.00	Low
8/2/2023	BMO Capital Markets	Boost Target	Market Perform ➝ Market Perform	$96.00 ➝ $100.00	Low
8/2/2023	Morgan Stanley	Reiterated Rating	Overweight ➝ Overweight	$130.00	N/A
8/2/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$108.00 ➝ $110.00	N/A
8/2/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$140.00	N/A
8/2/2023	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$130.00 ➝ $132.00	Low
8/2/2023	Cantor Fitzgerald	Boost Target		$127.00 ➝ $135.00	Low
8/2/2023	Mizuho	Boost Target	Neutral ➝ Neutral	$111.00 ➝ $112.00	Low
8/2/2023	Robert W. Baird	Boost Target	Outperform ➝ Outperform	$140.00 ➝ $148.00	Low
7/24/2023	SVB Leerink	Upgrade	Market Perform ➝ Outperform		Low
7/24/2023	SVB Securities	Upgrade	Market Perform ➝ Outperform	$115.00 ➝ $125.00	Low
7/6/2023	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$91.00 ➝ $96.00	Low
6/30/2023	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$108.00	Low
6/6/2023	Stifel Nicolaus	Lower Target		$145.00 ➝ $125.00	Low
6/5/2023	Royal Bank of Canada	Boost Target		$106.00 ➝ $108.00	Low
5/4/2023	Mizuho	Lower Target		$116.00 ➝ $111.00	Low
5/4/2023	Citigroup	Lower Target		$127.00 ➝ $122.00	Low
5/4/2023	Barclays	Lower Target		$131.00 ➝ $125.00	Low
5/4/2023	Guggenheim	Upgrade	Neutral ➝ Buy	$145.00	Low
4/24/2023	Royal Bank of Canada	Boost Target		$108.00 ➝ $110.00	Low
4/19/2023	Citigroup	Lower Target	Buy	$131.00 ➝ $127.00	Low
4/17/2023	Wedbush	Lower Target	Outperform	$131.00 ➝ $128.00	Low
4/14/2023	Mizuho	Reiterated Rating	Neutral	$116.00	Low
4/4/2023	UBS Group	Lower Target	Buy	$137.00 ➝ $125.00	Low
3/30/2023	Canaccord Genuity Group	Upgrade	Hold ➝ Buy	$124.00 ➝ $132.00	Low
3/3/2023	Evercore ISI	Upgrade	In-Line ➝ Outperform	$130.00	Low
2/7/2023	Royal Bank of Canada	Lower Target	Sector Perform	$122.00 ➝ $110.00	Low
2/7/2023	Wells Fargo & Company	Lower Target	Equal Weight	$120.00 ➝ $115.00	Low
2/7/2023	HC Wainwright	Reiterated Rating	Buy	$140.00	Low
2/7/2023	Mizuho	Reiterated Rating	Neutral	$116.00	Low
2/7/2023	Cantor Fitzgerald	Lower Target	Overweight	$132.00 ➝ $127.00	Low
2/7/2023	Wedbush	Boost Target	Outperform	$125.00 ➝ $131.00	Low
2/7/2023	Citigroup	Lower Target	Buy	$133.00 ➝ $131.00	Low
2/7/2023	Barclays	Lower Target	Overweight	$136.00 ➝ $131.00	Low
2/7/2023	Piper Sandler	Lower Target	Neutral	$103.00 ➝ $95.00	Low
2/3/2023	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$120.00 ➝ $130.00	Low
11/3/2022	Raymond James	Boost Target	Outperform	$125.00 ➝ $135.00	Low
11/3/2022	JPMorgan Chase & Co.	Boost Target	Overweight	$138.00 ➝ $143.00	Low
11/2/2022	Mizuho	Boost Target	Neutral	$105.00 ➝ $116.00	Low
11/2/2022	BMO Capital Markets	Boost Target		$78.00 ➝ $101.00	Low
11/2/2022	Morgan Stanley	Boost Target	Equal Weight	$102.00 ➝ $120.00	Low
11/2/2022	Wells Fargo & Company	Boost Target	Equal Weight	$110.00 ➝ $120.00	Low
11/2/2022	Royal Bank of Canada	Boost Target	Sector Perform	$101.00 ➝ $117.00	Low
11/2/2022	Cantor Fitzgerald	Boost Target	Overweight	$127.00 ➝ $132.00	Low
11/2/2022	Robert W. Baird	Boost Target		$125.00 ➝ $150.00	N/A
11/2/2022	Piper Sandler	Boost Target	Neutral	$91.00 ➝ $103.00	N/A
11/2/2022	SVB Leerink	Boost Target	Market Perform	$100.00 ➝ $115.00	Low
10/24/2022	Citigroup	Boost Target	Buy	$114.00 ➝ $128.00	Low
10/20/2022	Mizuho	Boost Target	Neutral	$98.00 ➝ $105.00	Low
10/11/2022	UBS Group	Initiated Coverage	Buy	$136.00	Low
9/26/2022	Wells Fargo & Company	Initiated Coverage	Equal Weight	$110.00	Low
8/8/2022	Mizuho	Boost Target	Neutral	$95.00 ➝ $98.00	Low
8/5/2022	Robert W. Baird	Boost Target		$117.00 ➝ $125.00	Low
8/5/2022	Barclays	Boost Target	Overweight	$110.00 ➝ $113.00	Low
7/15/2022	Morgan Stanley	Boost Target	Equal Weight	$100.00 ➝ $102.00	Low
4/28/2022	Wedbush	Reiterated Rating	Outperform		High
4/12/2022	Barclays	Boost Target	Overweight	$100.00 ➝ $110.00	Medium
4/4/2022	JPMorgan Chase & Co.	Boost Target	Overweight	$125.00 ➝ $126.00	Low
3/3/2022	Jefferies Financial Group	Downgrade	Hold	$94.00	Medium
3/3/2022	Piper Sandler	Downgrade	Overweight ➝ Neutral	$114.00 ➝ $94.00	High
2/24/2022	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$115.00	Low
2/14/2022	HC Wainwright	Reiterated Rating	Buy	$140.00	Low
2/14/2022	Morgan Stanley	Boost Target	Equal Weight	$95.00 ➝ $100.00	Medium
2/14/2022	Mizuho	Lower Target		$103.00 ➝ $95.00	Medium
2/11/2022	Raymond James	Reiterated Rating	Buy	$125.00	Medium
2/1/2022	Morgan Stanley	Lower Target	Equal Weight	$103.00 ➝ $95.00	Low
1/26/2022	Piper Sandler	Lower Target		$123.00 ➝ $114.00	Low
1/20/2022	Barclays	Lower Target	Overweight	$110.00 ➝ $100.00	Low
1/18/2022	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$122.00 ➝ $90.00	High
1/7/2022	HC Wainwright	Reiterated Rating	Buy	$140.00	High
1/7/2022	Morgan Stanley	Lower Target	Equal Weight	$112.00 ➝ $103.00	High
12/8/2021	HC Wainwright	Reiterated Rating	Buy	$139.00	Low
12/8/2021	Oppenheimer	Boost Target	Outperform ➝ Outperform	$140.00 ➝ $154.00	High
12/8/2021	Citigroup	Boost Target	Buy ➝ Buy	$127.00 ➝ $129.00	High
11/18/2021	BMO Capital Markets	Initiated Coverage	Underperform	$76.00	Low
11/17/2021	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$124.00	Low
11/2/2021	Citigroup	Lower Target	Buy	$132.00 ➝ $127.00	High
11/2/2021	Raymond James	Lower Target	Outperform	$163.00 ➝ $150.00	High
11/2/2021	Royal Bank of Canada	Lower Target	Outperform	$130.00 ➝ $119.00	High
11/2/2021	Mizuho	Boost Target	Neutral	$99.00 ➝ $103.00	High
11/2/2021	Cantor Fitzgerald	Boost Target	Overweight	$117.00 ➝ $123.00	High
10/18/2021	SVB Leerink	Reiterated Rating	Market Perform		Low
10/14/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$110.00 ➝ $112.00	Low
9/30/2021	HC Wainwright	Reiterated Rating	Buy		High
9/22/2021	Needham & Company LLC	Initiated Coverage	Hold		Low
8/4/2021	Morgan Stanley	Lower Target	Overweight	$116.00 ➝ $110.00	High
7/16/2021	HC Wainwright	Reiterated Rating	Buy	$140.00	Medium
5/18/2021	The Goldman Sachs Group	Initiated Coverage	Neutral	$108.00	Low
5/6/2021	Wedbush	Lower Target		$112.00 ➝ $107.00	Medium
5/6/2021	Oppenheimer	Lower Target		$145.00 ➝ $140.00	High
5/6/2021	Morgan Stanley	Lower Target	Overweight	$125.00 ➝ $116.00	High
5/6/2021	SVB Leerink	Lower Target	Market Perform	$110.00 ➝ $100.00	High
5/6/2021	Barclays	Upgrade	Equal Weight ➝ Overweight	$110.00	High
5/3/2021	Mizuho	Lower Target	Neutral	$119.00 ➝ $116.00	N/A
4/26/2021	Mizuho	Lower Target	In-Line ➝ Neutral	$119.00 ➝ $116.00	High
4/19/2021	Morgan Stanley	Boost Target	Overweight	$121.00 ➝ $125.00	Low
4/12/2021	Wedbush	Lower Target	Outperform	$126.00 ➝ $112.00	Medium
3/5/2021	Robert W. Baird	Reiterated Rating	Buy		High
2/5/2021	Mizuho	Boost Target	Neutral	$117.00 ➝ $119.00	High
2/1/2021	Raymond James	Initiated Coverage	Outperform	$163.00 ➝ $163.00	Low
1/26/2021	William Blair	Reiterated Rating	Buy		Medium
12/29/2020	Cantor Fitzgerald	Lower Target	Overweight	$168.00 ➝ $121.00	N/A
12/16/2020	Morgan Stanley	Lower Target	Overweight	$133.00 ➝ $121.00	Medium
12/7/2020	Wedbush	Lower Target	Outperform	$129.00 ➝ $121.00	High
11/10/2020	Oppenheimer	Lower Target		$150.00 ➝ $145.00	Medium
11/10/2020	Smith Barney Citigroup	Lower Target		$149.00 ➝ $138.00	Low
11/10/2020	William Blair	Reiterated Rating	Outperform		Low
11/10/2020	Wedbush	Lower Target	Outperform	$147.00 ➝ $129.00	Medium
11/10/2020	Credit Suisse Group	Lower Target	Neutral	$105.00 ➝ $90.00	High
11/10/2020	Mizuho	Lower Target	Neutral	$132.00 ➝ $117.00	High
11/10/2020	SVB Leerink	Lower Target	Market Perform	$120.00 ➝ $100.00	High
10/29/2020	Oppenheimer	Lower Target	Outperform	$155.00 ➝ $150.00	Low
9/30/2020	Benchmark	Initiated Coverage	Hold		High
8/4/2020	Credit Suisse Group	Lower Target	Neutral	$135.00 ➝ $126.00	High
8/4/2020	Morgan Stanley	Lower Target	Overweight	$149.00 ➝ $146.00	High
8/4/2020	HC Wainwright	Boost Target	Buy	$131.00 ➝ $140.00	High
8/4/2020	Cantor Fitzgerald	Boost Target	Overweight	$144.00 ➝ $161.00	High
8/4/2020	Mizuho	Boost Target	Neutral	$127.00 ➝ $132.00	High
8/4/2020	SVB Leerink	Boost Target	Market Perform	$105.00 ➝ $120.00	High
8/4/2020	Piper Sandler	Boost Target	Overweight	$141.00 ➝ $145.00	High
8/4/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$136.00	High
7/23/2020	Mizuho	Boost Target	Neutral	$105.00 ➝ $127.00	Medium
7/20/2020	Credit Suisse Group	Boost Target	Neutral	$101.00 ➝ $135.00	Medium
7/17/2020	Oppenheimer	Boost Target	Outperform	$142.00 ➝ $152.00	Medium
7/15/2020	Morgan Stanley	Boost Target	Overweight	$120.00 ➝ $149.00	Low
6/29/2020	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$135.00	High
6/26/2020	Citigroup	Boost Target	Buy	$124.00 ➝ $149.00	High
6/18/2020	JPMorgan Chase & Co.	Boost Target	In-Line ➝ Overweight	$122.00 ➝ $134.00	Medium
6/18/2020	Royal Bank of Canada	Boost Target	Outperform	$116.00 ➝ $135.00	Low
6/17/2020	HC Wainwright	Reiterated Rating	Buy	$125.00 ➝ $131.00	Low
6/16/2020	Needham & Company LLC	Initiated Coverage	Hold		Low
6/16/2020	Oppenheimer	Initiated Coverage	Buy	$142.00	Low
6/8/2020	Wedbush	Initiated Coverage	Outperform	$147.00	Low
6/1/2020	Piper Sandler	Reiterated Rating	Buy	$126.00	Low
5/7/2020	Barclays	Boost Target	Equal Weight	$105.00 ➝ $108.00	High
5/7/2020	Mizuho	Boost Target	Neutral	$103.00 ➝ $105.00	High
5/7/2020	Morgan Stanley	Lower Target	Buy	$121.00 ➝ $120.00	High
5/7/2020	HC Wainwright	Reiterated Rating	Buy	$125.00	High
5/7/2020	Needham & Company LLC	Reiterated Rating	Hold		High
4/30/2020	William Blair	Reiterated Rating	Buy		High
4/27/2020	Needham & Company LLC	Reiterated Rating	Hold		Medium
4/13/2020	Oppenheimer	Lower Target	Outperform	$132.00 ➝ $130.00	Low
4/8/2020	Piper Sandler	Lower Target		$147.00 ➝ $125.00	Medium
4/8/2020	Needham & Company LLC	Reiterated Rating	Hold ➝ Neutral		Medium
4/8/2020	Royal Bank of Canada	Reiterated Rating	Buy	$104.00	Medium
3/5/2020	Citigroup	Initiated Coverage	Buy	$124.00	Medium
2/27/2020	Barclays	Initiated Coverage	Equal Weight	$105.00	High
2/24/2020	William Blair	Initiated Coverage	Outperform	$116.00	High
2/14/2020	Stifel Nicolaus	Reiterated Rating	Buy	$127.00	N/A
2/5/2020	Mizuho	Initiated Coverage	Neutral	$107.00	Low
2/5/2020	HC Wainwright	Reiterated Rating	Buy	$102.00 ➝ $125.00	Medium
1/20/2020	Royal Bank of Canada	Reiterated Rating	Buy	$125.00	Low
1/17/2020	Morgan Stanley	Boost Target	Overweight	$120.00 ➝ $121.00	Medium
1/13/2020	Oppenheimer	Boost Target	Outperform	$115.00 ➝ $132.00	High
12/17/2019	Morgan Stanley	Boost Target	Overweight	$110.00 ➝ $120.00	Medium
12/13/2019	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$110.00	Low
12/12/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$116.00 ➝ $153.00	Medium
11/5/2019	Piper Jaffray Companies	Boost Target		$111.00 ➝ $116.00	Low
9/6/2019	Royal Bank of Canada	Set Target	Buy	$118.00	Medium
8/7/2019	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$118.00	Low
7/31/2019	Needham & Company LLC	Reiterated Rating	Hold		Medium
7/30/2019	Credit Suisse Group	Boost Target	Outperform	$95.00 ➝ $110.00	High
7/30/2019	Piper Jaffray Companies	Boost Target	Overweight	$103.00 ➝ $111.00	High
7/16/2019	CIBC	Initiated Coverage	Outperform ➝ Outperform	$100.00	Low
7/16/2019	Oppenheimer	Initiated Coverage	Outperform	$100.00	Low
7/15/2019	Stifel Nicolaus	Set Target	Buy	$113.00	Low
6/4/2019	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$88.00	Medium
5/20/2019	Credit Suisse Group	Initiated Coverage	Outperform	$95.00	Medium
4/22/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$100.00 ➝ $106.00	High
4/11/2019	Evercore ISI	Initiated Coverage	Outperform		Low
3/29/2019	Barclays	Reiterated Rating	Buy	$110.00	High
3/13/2019	Oppenheimer	Boost Target	Outperform	$105.00 ➝ $110.00	Medium
2/6/2019	Bank of America	Lower Target	Buy	$124.00 ➝ $117.00	Medium
2/6/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		High
1/30/2019	HC Wainwright	Reiterated Rating	Buy		Medium
1/29/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$121.00	Medium
1/29/2019	Oppenheimer	Set Target	Buy	$105.00	Medium
1/24/2019	Needham & Company LLC	Downgrade	Buy ➝ Hold		Low
1/23/2019	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$97.00 ➝ $100.00	Medium
1/15/2019	HC Wainwright	Reiterated Rating	Buy	$102.00	High
1/6/2019	Oppenheimer	Set Target	Buy	$105.00	High
12/13/2018	Oppenheimer	Lower Target	Outperform	$140.00 ➝ $105.00	Low
12/13/2018	JPMorgan Chase & Co.	Lower Target	Overweight	$127.00 ➝ $97.00	Low
12/13/2018	Robert W. Baird	Lower Target	Outperform	$131.00 ➝ $96.00	Medium
12/13/2018	SVB Leerink	Lower Target	Market Perform	$110.00 ➝ $84.00	Medium
12/13/2018	HC Wainwright	Reiterated Rating	Buy	$162.00	Medium
12/13/2018	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$103.00	Medium
12/13/2018	Barclays	Reiterated Rating	Buy	$95.00	Medium
12/12/2018	Stifel Nicolaus	Lower Target	Buy	$115.00 ➝ $17.07	High
12/12/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$121.00	High
12/12/2018	Needham & Company LLC	Set Target	Buy	$104.00	High
12/11/2018	Oppenheimer	Set Target	Buy	$140.00	High
12/5/2018	Cantor Fitzgerald	Set Target	Buy	$150.00	Low
11/12/2018	SVB Leerink	Initiated Coverage	Market Perform	$110.00	High
11/6/2018	Morgan Stanley	Lower Target	Overweight ➝ Buy	$145.00 ➝ $135.00	Low
11/6/2018	Piper Jaffray Companies	Set Target	Buy	$111.00	High
11/5/2018	Cantor Fitzgerald	Set Target	Buy	$150.00	High
11/5/2018	Oppenheimer	Set Target	Buy	$140.00	High
10/5/2018	Piper Jaffray Companies	Set Target	Buy	$115.00	Low

(Data available from 10/3/2018 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

11 very positive mentions
12 positive mentions
7 negative mentions
1 very negative mentions

Mentions as of

3/7/2023

14 very positive mentions
8 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/6/2023

15 very positive mentions
22 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

5/6/2023

12 very positive mentions
6 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

6/5/2023

18 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/5/2023

15 very positive mentions
21 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

8/4/2023

20 very positive mentions
8 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

9/3/2023

25 very positive mentions
14 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/3/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $110.15

$110.07

$111.89

50 Day Range

MA: $108.18

$100.38

$117.10

52 Week Range

Now: $110.15

$89.04

$129.29

Volume

89,690 shs

Average Volume

754,548 shs

Market Capitalization

$10.76 billion

P/E Ratio

63.67

Dividend Yield

N/A

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Neurocrine Biosciences?: The following Wall Street sell-side analysts have issued research reports on Neurocrine Biosciences in the last twelve months: Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, SVB Securities, TheStreet, UBS Group AG, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for NBIX.
What is the current price target for Neurocrine Biosciences?: 23 Wall Street analysts have set twelve-month price targets for Neurocrine Biosciences in the last year. Their average twelve-month price target is $128.52, suggesting a possible upside of 16.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting NBIX will reach $154.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $95.00 for Neurocrine Biosciences in the next year.
View the latest price targets for NBIX.
What is the current consensus analyst rating for Neurocrine Biosciences?: Neurocrine Biosciences currently has 5 hold ratings and 16 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NBIX.
What other companies compete with Neurocrine Biosciences?: Other companies that are similar to Neurocrine Biosciences include Repligen, Exelixis, Halozyme Therapeutics, Biogen and Seagen. Learn More about companies similar to Neurocrine Biosciences.
How do I contact Neurocrine Biosciences' investor relations team?: Neurocrine Biosciences' physical mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company's listed phone number is (858) 617-7600 and its investor relations email address is [email protected]. The official website for Neurocrine Biosciences is www.neurocrine.com. Learn More about contacing Neurocrine Biosciences investor relations.

Neurocrine Biosciences - NBIX Stock Price Target and Predictions

Analyst Price Target for NBIX

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.05 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Neurocrine Biosciences?

What is the current price target for Neurocrine Biosciences?

What is the current consensus analyst rating for Neurocrine Biosciences?

What other companies compete with Neurocrine Biosciences?

How do I contact Neurocrine Biosciences' investor relations team?